Two things were introduced in the pan-Canadian action plan and the recommendations; they are push-and-pull incentives.
The push incentive is for Canadian innovators to be able to take their innovations at their universities and produce them. There are mechanisms that apply. We mentioned HERC. In the United States there's small business innovation research, SBIR. We need those mechanisms for Canadian innovators.
With newer antibiotics that are introduced on the market, we are talking about pull incentives. As I mentioned before, the pull incentives are to incentivize companies to bring their products into the country here.
We have been talking about pull incentive pilots. Unfortunately, we're becoming known as the country of pilots, where pilots are adopted, but they take a long time. They need be done in consultation with industry. The stakeholders are the companies. If they want to bring their products into Canada, the pilots—the incentives—have to be workable. They have to be something they can work with. We cannot introduce a pilot that's going to make it even more complicated for the company to bring the product, because they will never do that. That's what we're seeing.
We are now asking the government to really stand behind PHAC, the Public Health Agency, in working on the pilots to make sure that there is sufficient funding. I mentioned that the commitments we're asking for from the Canadian government are from $11 million to $21 million for the pull incentive to bring their products. The manufacturing can take place in Canada here so we can be sufficient as far as the supply chain is concerned, if those products come into Canada.